ClinicalTrials.gg
CompletedNCT06355531Updated Nov 16, 2026

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

A Phase 2 interventional study of FNP-223 and Placebo in Progressive Supranuclear Palsy, sponsored by Ferrer Internacional S.A.. Completed at 44 sites in 9 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Ferrer Internacional S.A. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Supranuclear Palsy, Progressive with a site in United States — 19 open to participants now, 25 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · United States.

Enrollment
12th of 52
241 · median 43
Started
2024
with 1 other
Phase 2
11 of 84
3 open now
Registered
73rd of 84
by date

Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, this one is the 12th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 in phase 2, and was the 73rd registered.

Supranuclear Palsy, Progressive

171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.

Browse Supranuclear Palsy, Progressive studies →

Open to participants now

19 of the 84 studies in Supranuclear Palsy, Progressive with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Supranuclear Palsy, Progressive with a site in United States, or all of them as a file.
02

Study summary

PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.

03

Conditions studied

  • Progressive Supranuclear Palsy

Keywords

  • Progressive Supranuclear Palsy
  • Disease progression
  • FNP-223
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 50 to 80 years, inclusive, at the time of .
  • Diagnosis of possible or probable PSP of the Richardson's Syndrome (PSP-RS) phenotypes according to the Movement Disorders Society's Progressive Supranuclear Palsy (MDS PSP) clinical features criteria. At least 1 (either 1 or both) of the following 2 items must be met:

    1. Vertical supranuclear gaze palsy.
    2. Slowing of vertical saccades AND postural instability with falls within the first 3 years of PSP symptoms.
  • Presence of PSP symptoms within ≤3 years prior to screening.
  • score ≥23
  • Full 28-item PSPRS score ≤40.
  • Able to ambulate independently or with minimal assistance defined as the ability to take at least 10 steps (stabilization of 1 arm [ie, use of cane]).
  • Body weight range ≥43 kg/95 lbs to ≤120 kg/265 lbs.
  • Reside outside a skilled nursing facility or dementia care facility, except for participants residing in an assisted living facility.
  • Has a caregiver or study partner who will accompany them to the study visits. The caregiver or study partner must be a person who has frequent contact (at least 7 hours per week at 1 time or in different days) with the participant and is able to provide information about the participant's medication and overall condition. Prior to the conduct of any study procedures, the caregiver or study partner must be willing to sign the independent ethics committee (IEC)/institutional review board (IRB) approved informed consent.

Exclusion criteria

Exclusion Criteria:

Non-PSP- RS Movement Disorders or other central nervous system (CNS) Diseases

  • Score of 3 on any functional domain in the PSP-CDS.
  • Participants with known PSP genetic mutation (based on familiar or clinical history).
  • Evidence of other neurological disorder that could explain signs of PSP (eg, Parkinson's disease, Alzheimer disease, etc.).
  • Brain magnetic resonance imaging (MRI) within 1 year of screening consistent with:
  • Primary degenerative diseases other than PSP.

Procedures

  • For the optional substudy only: or refusal to undergo 2 lumbar punctures for obtaining CSF.
  • Contraindication or inability to tolerate MRI for screening MRI and volumetric brain MRI assessments throughout the substudy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    FNP-223

    Participants will receive FNP-223 orally (PO), 3 times daily (TID).

    Drug: FNP-223

  • Placebo comparator
    Placebo

    Participants will receive matching placebo, PO, TID.

    Drug: Placebo

Interventions

  • DrugFNP-223

    Oral tablets

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 52 in the PSPRS Outcome

    Time frame: Baseline to Week 52

  2. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Clinically significant changes in vital signs, clinical laboratory evaluations, physical examinations, and electrocardiogram (ECG) are included in TEAEs.

    Time frame: Baseline to Week 52

  3. Number of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline to Week 52 in Clinical Global Impression of Severity Scale (CGI-S)

    Time frame: Baseline to Week 52

  2. Change From Baseline to Week 52 Participant Global Impression of Severity Scale (PGI-S)

    Time frame: Baseline to Week 52

  3. Change From Baseline to Week 52 in Caregiver Global Impression of Severity Scale (CaGI-S)

    Time frame: Baseline to Week 52

  4. Slope of Decline in PSPRS

    Time frame: Baseline to Week 52

  5. Change From Baseline to Week 52 in Individual Subitems of PSPRS

    Time frame: Baseline to Week 52

  6. Change From Baseline to Week 52 in Schwab and England Activities of Daily Living Scale

    Time frame: Baseline to Week 52

  7. Change From Baseline to Week 52 in PSP Clinical Deficits Scale (PSP-CDS)

    Time frame: Baseline to Week 52

  8. Change From Baseline to Week 52 in Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline to Week 52

  9. Change From Baseline to Week 52 in PSP Quality of Life Scale (PSP-QoL)

    Time frame: Baseline to Week 52

  10. Pharmacokinetic characterization of FNP-223

    Mean plasma concentration of FNP-223.

    Time frame: At Week 4 and Week 16

07

Study locations

44 sites
08

References and documents

Publications

  • Pokorny R, Ryan JM, Abd-Elaziz K, van den Berg F, Rabiner E, Searle GE, Schneider M, Wiessner C, Stallaert JF, Permanne B, Quattropani A, Beher D. Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in Healthy Participants. Mov Disord. 2026 Feb;41(2):436-444. doi: 10.1002/mds.70104. Epub 2025 Nov 15. PubMed 41239890 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2024 to primary completion in Oct 2026, 26 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Nov 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 9, 2024
StartActual
Jul 23, 2024
Primary completionActual
Oct 5, 2026was Nov 2026
CompletionActual
Oct 29, 2026was Nov 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Primary completion
Nov 2026→Oct 5, 2026 (actual)
Nov 16, 2026
Study completion
Nov 2026→Oct 29, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Primary completion Nov 2026→Oct 5, 2026 (now actual)
    Study completion Nov 2026→Oct 29, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06355531
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Jul 23, 2024
Primary completion
Oct 5, 2026
Completion
Oct 29, 2026
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion